Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a Healthcare company (Biotechnology) with a market capitalization of $1.7B. The Maz Rating grades it against the other companies in its sector.
Recursion Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.72, Recursion Pharmaceuticals, Inc. trades at 24.6x sales and 1.6x book value. Over the last twelve months it generated about $69M of revenue and a net loss of $567M. It runs a gross margin of 10.7%, an operating margin of -725.4% and a net margin of -697.1%. It shows return on equity of -47.8%, return on invested capital of -43.7% and a free cash flow yield of -18.6%. On the balance sheet: a debt-to-equity ratio of 0.08 and a current ratio of 5.01. Over the past 52 weeks the share price ranged from $2.50 to $5.24, with a beta of 1.03.
Recursion Pharmaceuticals, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 4 Buy and 6 Hold, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.